An analysis of data from health insurance databases for patients with non-valvular atrial fibrillation treated with dabigatran etexilate or warfarin for prevention of stroke

Trial Profile

An analysis of data from health insurance databases for patients with non-valvular atrial fibrillation treated with dabigatran etexilate or warfarin for prevention of stroke

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2017 Results (n=21735)published in the Boehringer Ingelheim Pharmaceuticals media release.
    • 11 Nov 2015 Interim results presented at the 88th Annual Scientific Sessions of the American Heart Association.
    • 10 Nov 2015 According to a Boehringer Ingelheim media release, interim analysis results of this study were presented at the American Heart Association (AHA) Scientific Sessions 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top